Skip to main content

LION Licenses New EST Clustering Software to Intervet: Mar 6, 2001 (rev. 2)

NEW YORK, March 6 – Lion Bioscience has licensed its soon-to-be launched EST clustering analysis software everEST, as well as genomeScout, its genome analysis software, to the Netherlands-based animal health company Intervet International, Lion said Tuesday.

Lion has also extended existing licenses for its SRS data integration platform and its bioScout genomic annotation system to Intervet.

“Intervet is a valuable customer with a broad experience in bioinformatics,” Christian Marcazzo, Lion’s director of product marketing, told GenomeWeb.

Lion said this new extended software licensing agreement will provide additional revenue, but Marcazzo declined to comment on its financial terms.

Intervet is the second company to license and implement everEST. Lion has also installed the software, which it will officially launch this spring, at Nestle.

EverEST is designed to retrieve data from Lion’s SRS platform and perform EST clustering on it. “For the first time, the user can retrieve biological information concerning ESTs and EST consensus sequences from all major biological databases,” Marcazzo said. “Built-in applications can be launched to further analyze consensus sequences, such as BLAST or LION's annotation application bioScout.”

The everEST system incorporates the StackPack clustering engine, which Lion non-exclusively licensed last fall from Electric Genetics in South Africa.

StackPack includes data management and visualization tools that enable researchers to rapidly cluster, align, and analyze high volumes of ESTs and partial-length sequences. These tools highlight variations in transcripts and can accelerate gene discovery, gene function analysis, expression analysis and drug development.

Lion has established partnerships with a number of Life Science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithkline, Janssen, Merck, Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Sumitomo Pharmaceuticals, and Tripos. SRS is currently used by more than 30 life science organizations to integrate more than 400 different databases, the company said.  
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.